COMMUNIQUÉS West-GlobeNewswire

Revuforj® (revumenib) Named Best New Drug at the Scrip Awards 2025
12/12/2025
NEW YORK, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Revuforj ® (revumenib) was [...]
BioCryst Announces FDA Approval of ORLADEYO® (berotralstat) Oral Pellets, First and Only Oral Prophylactic Treatment for Patients with HAE Aged 2 to <12 Years
12/12/2025
– ORLADEYO now first and only targeted oral prophylactic therapy for patients with HAE aged 2 and older – -Oral pellet formulation provides child-friendly method of administration- –Showed early and sustained reductions [...]
Novartis breaks ground on flagship manufacturing hub in North Carolina
12/12/2025
FDA Commissioner Marty Makary, North Carolina Governor Josh Stein and Novartis leadership highlight importance of new hub to US patients and local economy Construction reflects company’s commitment to ensure end-to-end [...]
Clearmind Medicine Successfully Regains Compliance with Nasdaq's Minimum Stockholders' Equity Requirement
12/12/2025
Vancouver, Canada, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel [...]
EssilorLuxottica to acquire Signifeye, further growing its ophthalmology clinics footprint
12/12/2025
EssilorLuxottica to acquire Signifeye, further growing its ophthalmology clinics footprint Paris, France (12 December 2025) – EssilorLuxottica announced today the acquisition of Signifeye, a leading Belgian [...]
EssilorLuxottica va acquérir Signifeye, poursuivant l’extension de son réseau de cliniques ophtalmologiques
12/12/2025
EssilorLuxottica va acquérir Signifeye, poursuivant l’extension de son réseau de cliniques ophtalmologiques Paris, France (12 décembre 2025) – EssilorLuxottica a annoncé aujourd’hui l’acquisition de Signifeye, une [...]
Genmab Announces Completion of Tender Offer for Outstanding Common Shares of Merus N.V. and Commencement of Subsequent Offering Period
12/12/2025
Company Announcement Transaction adds petosemtamab, a late-stage asset with two Breakthrough Therapy Designations, to Genmab’s portfolio Transaction anticipated to be accretive to Genmab’s EBITDA by end of 2029 [...]
Poppins Launches Integrated Pediatric Care Platform to Support Working Parents with Medical, Behavioral, and Coaching Services
12/12/2025
New York, NY, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Poppins has announced the launch of its integrated pediatric care platform designed to support working parents with medical, behavioral, and coaching services in one [...]
MedSpa Marketing Partners Unveils NORA: The AI Revolution in MedSpa Client Engagement
12/12/2025
SACRAMENTO, Calif., Dec. 12, 2025 (GLOBE NEWSWIRE) -- MedSpa Marketing Partners launches NORA, an AI-powered voice agent, transforming client engagement and appointment bookings for medical spas 24/7. Introduction: A [...]
Tenaya Therapeutics Announces Pricing of Public Offering
12/12/2025
SOUTH SAN FRANCISCO, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (Nasdaq: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative [...]
Sienna Announces Offering of $250 Million of 3.524% Series F Senior Unsecured Debentures and Redemption of C$175 Million of Series B Senior Unsecured Debentures
12/12/2025
NOT FOR DISSEMINATION TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES This news release constitutes a “designated news release” for the purposes of Sienna’s amended and restated prospectus [...]
Surgery Partners, Inc. Announces Pricing of Add-On Notes Offering
12/12/2025
BRENTWOOD, Tenn., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Surgery Partners, Inc. (NASDAQ:SGRY) (“Surgery Partners” or the “Company”) today announced that its wholly-owned subsidiary, Surgery Center Holdings, Inc. (the “Issuer [...]
Independent Study Presented at American Society of Hematology (ASH) Annual Meeting Concludes Remestemcel-L Superior to Ruxolitinib in Clinical Outcomes as Treatment for SR-aGvHD
12/12/2025
NEW YORK, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that an independent peer-reviewed [...]
Cycle Pharmaceuticals to Acquire Applied Therapeutics
11/12/2025
Applied Therapeutic’s lead drug candidate, govorestat, is a novel central nervous system penetrant Aldose Reductase Inhibitor for the treatment of CNS rare metabolic diseases NEW YORK, Dec. 11, 2025 (GLOBE NEWSWIRE) -- [...]
Microbix Schedules Release of Results for Q4 Fiscal 2025
11/12/2025
Results Release and Webinar Discussion on Morning of December 18, 2025 MISSISSAUGA, Ontario, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. ( TSX: MBX, OTCQX: MBXBF, Microbix® ), a life sciences innovator, [...]
The Joint Corp. Signs Asset Purchase Agreement to Sell 22 Corporate Clinics in the Southeast and Delivers Notice to Terminate APA for 45 Clinics in California
11/12/2025
Southeast Buyers are Existing Members of the Franchise Community, Further Increasing their Ownership SCOTTSDALE, Ariz., Dec. 11, 2025 (GLOBE NEWSWIRE) -- The Joint Corp. (NASDAQ: JYNT), the nation's largest franchisor [...]
FDA Approves the Zenflow Spring® Implant and Delivery System for First-Line Interventional Therapy of Patients with Benign Prostatic Hyperplasia (BPH)
11/12/2025
Long-Term Data Supports Three-Year Durability Innovative Design Allows for Only Tailored BPH Approach that Preserves Natural Anatomy SOUTH SAN FRANCISCO, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Zenflow, Inc . [...]
Serina Therapeutics Strengthens Leadership Team with Appointment of Dr. Joshua Thomas as VP, Head of Chemistry
11/12/2025
HUNTSVILLE, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina” or the "Company") (NYSE American: SER), a clinical-stage biotechnology company advancing its lead Investigational New Drug ("IND") [...]
Terns Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
11/12/2025
FOSTER CITY, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage oncology company, today announced the closing of its previously announced [...]

Pages